In summary, by using clinically expanded ICI cohorts, we uncovered that SETBP1 mutations were associated with favorable tumor immunogenicity and determined the sensitivity to cancer immunotherapies, which provides a potential biomarker for evaluating cancer ICI treatment response. The gene discussed is SETBP1; the disease is cancer.